for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tonix Pharmaceuticals Holding Corp

TNXP.OQ

Latest Trade

1.04USD

Change

0.01(+0.49%)

Volume

605,940

Today's Range

1.01

 - 

1.04

52 Week Range

0.51

 - 

2.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.03
Open
1.02
Volume
605,940
3M AVG Volume
678.00
Today's High
1.04
Today's Low
1.01
52 Week High
2.46
52 Week Low
0.51
Shares Out (MIL)
323.92
Market Cap (MIL)
332.02
Forward P/E
-4.90
Dividend (Yield %)
--

Next Event

Tonix Pharmaceuticals Holding Corp Annual Shareholders Meeting

Latest Developments

More

Tonix Pharmaceuticals Enters Into Exclusive Worldwide Licensing Agreement With Oyagen To Develop Antiviral Sars-Cov-2 Inhibitor, TNX-3500, For Treatment Of Covid-19

Tonix Pharma Says Data Shows TNX-1800 Induces Protection Against SARS-COV-2 Infection In Non-Human Primates

Tonix Pharmaceuticals Reports Q4 Loss Per Share Of $0.10

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).

Industry

Biotechnology & Drugs

Contact Info

26 MAIN STREET, SUITE 101

CHATHAM, NJ

07928

United States

+1.212.9809155

https://www.tonixpharma.com/

Executive Leadership

Seth Lederman

Chairman of the Board, President, Chief Executive Officer

Bradley Saenger

Chief Financial Officer, Treasurer

Jessica Edgar Morris

Chief Operating Officer

Herbert W. Harris

Executive Vice President - Translational Medicine

Gregory M. Sullivan

Secretary, Chief Medical Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-268.100

2019

-19.330

2020

-0.550

2021(E)

-0.210
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.41
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-103.21
Return on Equity (TTM)
-89.52

Latest News

Latest News

BRIEF-Tonix Pharmaceuticals Plans Massachusetts Research, Development Facility To Accelerate Clinical Development Of Vaccines, Protein-Based Therapeutics

* TONIX PHARMACEUTICALS PLANS MASSACHUSETTS RESEARCH AND DEVELOPMENT FACILITY TO ACCELERATE CLINICAL DEVELOPMENT OF VACCINES AND PROTEIN-BASED THERAPEUTICS

BRIEF-Tonix Announces Enrollment Of Phase 3 Relief Trial Of Tnx-102 Sl For Management Of Fibromyalgia Is Ahead Of Schedule

* TONIX PHARMACEUTICALS ANNOUNCES ENROLLMENT OF PHASE 3 RELIEF TRIAL OF TNX-102 SL FOR MANAGEMENT OF FIBROMYALGIA IS AHEAD OF SCHEDULE

BRIEF-Tonix Pharmaceuticals, Southern Research Announce Expansion Of COVID-19 Vaccine Collaboration

* TONIX PHARMACEUTICALS AND SOUTHERN RESEARCH ANNOUNCE EXPANSION OF COVID-19 VACCINE COLLABORATION

BRIEF-Tonix Pharma Announces Appointment Of Richard H. Bagger To Board

* TONIX PHARMACEUTICALS ANNOUNCES APPOINTMENT OF RICHARD H. BAGGER TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Tonix Pharma Reports Fujifilm Diosynth To Be Manufacturing Partner For Covid-19 Vaccine Candidate

* TONIX PHARMACEUTICALS ANNOUNCES FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO BE MANUFACTURING PARTNER FOR COVID-19 VACCINE CANDIDATE TNX-1800 Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharma Posts Results From Pharmacokinetic Analyses Of TNX-102 SL And TNX-601 CR

* TONIX PHARMACEUTICALS POSTED RESULTS FROM PHARMACOKINETIC ANALYSES OF TNX-102 SL AND TNX-601 CR IN ADVANCE OF VIRTUAL POSTER PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com...

BRIEF-Tonix Pharmaceuticals Says Will Present Details About Vaccine Candidates Targeting COVID-19 On May 19

* TONIX PHARMACEUTICALS - WILL PRESENT CERTAIN INFORMATION REGARDING ITS VACCINE CANDIDATES TARGETING COVID-19 AT A PANEL ON MAY 19 Source text: (https://bit.ly/3fURWwv) Further company coverage:

BRIEF-Tonix Pharmaceuticals - U.S. FDA Informed Co That Breakthrough Therapy Designation Was Rescinded For Tnx-102 Sl For Post-Traumatic Stress Disorder Treatment

* TONIX PHARMACEUTICALS - U.S. FDA INFORMED CO THAT BREAKTHROUGH THERAPY DESIGNATION WAS RESCINDED FOR TNX-102 SL FOR POST-TRAUMATIC STRESS DISORDER TREATMENT Source text for Eikon: https://bit.ly/2L8YrOe Further company coverage:

BRIEF-Tonix Pharmaceuticals Enters Agreement With University Of Alberta To Develop COVID-19 Vaccines

* TONIX PHARMACEUTICALS ENTERS INTO RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA TO DEVELOP NOVEL HORSEPOX-BASED VACCINES, TNX-1810, TNX-1820 AND TNX-1830, FOR THE PREVENTION OF COVID-19

BRIEF-Tonix Pharmaceuticals Achieves 50 Percent Enrollment In Phase 3 Relief Study Of Tnx-102 Sl

* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 RELIEF STUDY OF TNX-102 SL (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR MANAGEMENT OF FIBROMYALGIA

BRIEF-Tonix Pharma Files For Mixed Shelf Of Up To $150 Million

* TONIX PHARMACEUTICALS HOLDING CORP FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: (https://bit.ly/2Xp9gD9) Further company coverage:

BRIEF-Tonix Pharmaceuticals Enters Sales Agreement With A.G.P./Alliance Global Partners

* ENTERED INTO A SALES AGREEMENT WITH A.G.P./ALLIANCE GLOBAL PARTNERS

BRIEF-Tonix Pharmaceuticals Reports Q4 Loss Per Share Of $2.86

* TONIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Tonix Pharmaceuticals Inc Prices $16,005,000 Common Stock Offering Priced At-The-Market

* TONIX PHARMACEUTICALS, INC. PRICES $16,005,000 COMMON STOCK OFFERING PRICED AT-THE-MARKET

BRIEF-Tonix Pharma Prices $7.5 Mln Public Offering

* TONIX PHARMACEUTICALS PRICES $7.5 MILLION PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals Holding Corp Enters Into Sales Agreement With Cowen And Co

* TONIX PHARMACEUTICALS HOLDING CORP SAYS ON MAY 1, CO ENTERED INTO SALES AGREEMENT WITH COWEN AND CO RELATING TO SHARES OF CO'S COMMON STOCK OFFERED

BRIEF-Tonix Pharmaceuticals Posts Q1 Loss Of $0.88 Per Share

* TONIX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

BRIEF-Tonix Pharmaceuticals Holding Qtrly Net Loss Per Common Share $0.88

* TONIX PHARMACEUTICALS HOLDING CORP QTRLY NET LOSS PER COMMON SHARE $0.88 Source text: (https://bit.ly/2G8HkXY) Further company coverage:

BRIEF-Tonix Pharmaceuticals Holding Says Files For Mixed Shelf Of Up To $75 Mln

* TONIX PHARMACEUTICALS HOLDING SAYS FILES FOR MIXED SHELF OF UP TO $75 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KqLRZ4) Further company coverage:

BRIEF-Tonix Pharmaceuticals Receives IND Clearance By U.S. FDA For TNX-102 SL

* TONIX PHARMACEUTICALS RECEIVES IND CLEARANCE BY U.S. FDA FOR TNX-102 SL IN AGITATION IN ALZHEIMER’S DISEASE Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up